Your browser doesn't support javascript.
loading
Upregulated lncRNA NORAD can diagnose acute cerebral ischemic stroke patients and predict poor prognosis.
Liu, Dongliang; Li, Li; Xu, Juanjuan; Luo, Wenping; Pan, Lu; Niu, Qilin; Wei, Daoxiang.
Afiliación
  • Liu D; Department of Neurology, The First Affiliated Hospital of Bengbu Medical College, Bengbu, China.
  • Li L; Department of Neurology, The First Affiliated Hospital of Bengbu Medical College, Bengbu, China.
  • Xu J; Department of Neurology, The First Affiliated Hospital of Bengbu Medical College, Bengbu, China.
  • Luo W; Department of Neurology, The First Affiliated Hospital of Bengbu Medical College, Bengbu, China.
  • Pan L; Department of Neurology, The First Affiliated Hospital of Bengbu Medical College, Bengbu, China.
  • Niu Q; Department of Neurology, The First Affiliated Hospital of Bengbu Medical College, Bengbu, China.
  • Wei D; Department of Neurology, The First Affiliated Hospital of Bengbu Medical College, Bengbu, China.
Folia Neuropathol ; 61(1): 105-110, 2023.
Article en En | MEDLINE | ID: mdl-37114966
INTRODUCTION: Acute cerebral ischemic stroke (AIS) dramatically influences patients' quality of life. lncRNA NORAD (NORAD) has been studied in cerebrovascular diseases, which are potential risk factors for AIS. The specific significance of NORAD is unclear. This study aimed to assess the role of NORAD in AIS, and to provide therapeutic value for its' treatment. MATERIAL AND METHODS: A total of 103 AIS patients and 95 healthy individuals (control) were enrolled into this study. Expression level of NORAD in the plasma of all participants was analyzed by PCR. Diagnostic potential of NORAD in AIS was evaluated by ROC analysis, while Kaplan-Meier and Cox regression analyses were conducted to assess its' prognostic value in AIS. RESULTS: A significantly increased level of NORAD was observed in AIS patients compared with healthy individuals. The upregulation of NORAD could dramatically discriminate AIS patients from healthy individuals with high sensitivity (81.60%) and specificity (88.40%). NORAD was positively correlated with patients' high-sensitivity C-reactive protein (hs CRP, r = 0.796), matrix metalloproteinase-9 (MMP9, r = 0.757), and NIHSS scores ( r = 0.840), and negatively related to pc-ASPECTS scores ( r = -0.607). Moreover, NORAD upregulation was associated with patients' unfavorable prognosis and served as an independent prognostic biomarker, together with NIHSS and pc-ASPECTS scores of AIS patients. CONCLUSIONS: NORAD was upregulated in AIS, which can discriminate AIS patients, and was closely correlated with severe development and poor prognosis of patients.
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Accidente Cerebrovascular / ARN Largo no Codificante / Accidente Cerebrovascular Isquémico Tipo de estudio: Diagnostic_studies / Prognostic_studies / Risk_factors_studies Aspecto: Patient_preference Límite: Humans Idioma: En Revista: Folia Neuropathol Asunto de la revista: NEUROLOGIA / PATOLOGIA Año: 2023 Tipo del documento: Article País de afiliación: China Pais de publicación: Polonia
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Accidente Cerebrovascular / ARN Largo no Codificante / Accidente Cerebrovascular Isquémico Tipo de estudio: Diagnostic_studies / Prognostic_studies / Risk_factors_studies Aspecto: Patient_preference Límite: Humans Idioma: En Revista: Folia Neuropathol Asunto de la revista: NEUROLOGIA / PATOLOGIA Año: 2023 Tipo del documento: Article País de afiliación: China Pais de publicación: Polonia